亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

湖北省帝鑫化工制造有限公司  

醫藥原料及中間體、植物提取物、動植物提取物等

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:胡鑫
  • 電話:027-51013021
  • 郵件:dxhg007@163.com
  • 傳真:027-67880806
  • QQ:1036188341
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 5-甲基脲嘧啶CAS65-71-4,廠價現貨
5-甲基脲嘧啶CAS65-71-4,廠價現貨
單價 1.00 / 千克對比
銷量 暫無
發貨 湖北武漢市付款后3天內
庫存 5000千克起訂25千克
品牌 帝鑫
過期 長期有效
更新 2016-01-14 16:08
 
詳細信息
 中文名稱:5-甲基脲嘧啶
英文名稱:5-METHYLURACIL
中文別名:2,4-二羥基-5-甲基嘧啶,胸腺嘧啶,胸嘧啶
英文別名:2,4-DIHYDROXY-5-METHYLPYRIMIDINE 5-METHYLURACIL,THYMIN,THYMINE
CAS號: 65-71-4 
分子式:C5H6N2O2 
分子量:126.11 
 
密度: 1.226g/cm3 
熔點: 316-317℃ 
沸點: 403.8°C at 760 mmHg 
閃點: 198°C 
蒸汽壓: 4.25E-07mmHg at 25°C
外  觀:白色結晶粉末,常溫難溶于水。
 
用途:一種是遺傳物質的重要組成部分,是合成抗艾滋病藥物AZT、DDT及相關藥物的關鍵中間體。 
©2025 湖北省帝鑫化工制造有限公司 版權所有   技術支持:化工網   訪問量:41057  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |